SuperworthRafael market cap RFL
Share price times shares outstanding: what the whole company sells for, since 2018.
- Today, Oct 23, 2026
- $68.1M
- Highest close in our data
- $1.1B
- Jul 2021
Rafael is worth $68.1M at the close on Oct 23, 2026, at $1.31 a share.
That is up 44% over the last year and down 56% over five years.
Its highest close in our data was $1.1B in Jul 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $68.1M | $60M | $163.8M | +10% |
| 2025 | $62.1M | $34.6M | $75.6M | +58% |
| 2024 | $39.2M | $33.4M | $58.2M | −13% |
| 2023 | $44.8M | $37.7M | $60.3M | −2% |
| 2022 | $45.8M | $36.2M | $102.9M | −57% |
| 2021 | $105.6M | $105.6M | $1.1B | −71% |
| 2020 | $369.2M | $164.5M | $386.3M | +29% |
| 2019 | $286.6M | $107M | $400.5M | +175% |
| 2018 | $104.1M | $100M | $127.5M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Rafael's size, closest first, today.
| Company | Market cap |
|---|---|
| RFLRafael | $68.1M |
| SPROSpero Therapeutics | $64.6M |
| LFVNLifevantage | $73.4M |
| ATNMActinium Pharmaceuticals | $47.8M |
| NATRNatures Sunshine Products | $213.8M |
| ARVNArvinas | $477.3M |
| PBYIPuma Biotechnology | $568.9M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $582.6M |
| CRMDCorMedix | $611.9M |
| Peer median | $477.3M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Rafael
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.